Three days after parathyroidectomy, a patient on triiodothyronine (T3) for pain developed a small itchy pinpoint rash limited to the anterior chest and base of neck without erythema or systemic signs; is this more likely a drug eruption or a contact/irritant dermatitis from the surgical skin preparation?

Localized Itchy Rash After Parathyroidectomy: Contact Dermatitis vs. Drug Eruption

This is almost certainly contact or irritant dermatitis from the surgical skin preparation (chlorhexidine or povidone-iodine), not a drug eruption from T3. The anatomical distribution limited to the surgical field (anterior chest and base of neck) is the key diagnostic feature that strongly favors a localized contact reaction over a systemic drug eruption.

Clinical Reasoning

Why Contact/Irritant Dermatitis is Most Likely:

The distribution pattern is diagnostic. The rash is confined precisely to where surgical skin preparation would have been applied—the anterior chest and base of neck—with complete sparing of other body areas. This anatomical restriction is pathognomonic for contact dermatitis 1, 2.

• Irritant contact dermatitis occurs in all individuals exposed to sufficient concentrations of irritants (dose-dependent), presenting with erythema, edema, and pruritus 1, 3
• Allergic contact dermatitis occurs in sensitized individuals, typically developing 24-48 hours after exposure 1, 2
• Chlorhexidine is a well-recognized cause of contact dermatitis in surgical settings, with allergy being more common than to povidone-iodine 4, 1

Why Drug Eruption from T3 is Unlikely:

Drug eruptions from systemically administered medications typically present with widespread, symmetric distribution, not localized pinpoint lesions confined to one anatomical region 5, 6.

• Eczematous drug eruptions from systemic medications are "scattered, widespread, generalized" 6
• T3 (liothyronine) is structurally identical to endogenous thyroid hormone; true allergic reactions are exceedingly rare and typically caused by excipients (fillers, dyes) in oral formulations 7
• When drug eruptions do occur from thyroid preparations, they manifest as generalized reactions, not localized to surgical sites 7
• The FDA labeling for triiodothyronine does not list localized rash as an adverse effect 8

Timing Considerations

The 3-day post-operative timeline fits both contact dermatitis (delayed hypersensitivity typically peaks 48-72 hours after exposure) and the typical window for recognizing irritant reactions 1, 2, 3.

Management Approach

Your patient's plan is appropriate:

1. Antihistamines (oral H1-antihistamines) for symptomatic relief of pruritus 1, 2
2. Topical corticosteroids to reduce inflammation and accelerate resolution 1, 2, 9
3. Emollients to restore skin barrier function 2, 9

Additional Recommendations:

• Avoid further exposure to the suspected surgical preparation agent 2, 9
• If the rash persists beyond 1-2 weeks or worsens despite treatment, consider patch testing to identify the specific allergen (chlorhexidine, povidone-iodine, or other surgical preparation components) 2
• Document this reaction in the medical record for future surgical procedures 4

Critical Pitfalls to Avoid:

• Do not discontinue T3 based on this localized rash—there is no evidence linking it to the medication
• Monitor for signs of true surgical complications: While this appears benign, remain vigilant for wound infection or hematoma, which can present with localized swelling and discomfort in the post-thyroidectomy period 10, 11
• Watch for systemic allergic symptoms: If the patient develops widespread rash, facial swelling, respiratory symptoms, or hemodynamic instability, this would require immediate reassessment for anaphylaxis or severe drug reaction 4

The localized, anatomically restricted nature of this rash makes contact/irritant dermatitis from surgical skin preparation the clear diagnosis, and symptomatic treatment with antihistamines and topical corticosteroids is the appropriate management.